SP
JAZZ icon

Symmetry Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Symmetry Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,471
Closed -$210K – 376
2019
Q1 		$210K Buy
1,471
+245
+20% +$32K 0.04% 293
2018
Q4 		$152K Buy
+1,226
New +$182K 0.04% 295

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Symmetry Partners's JAZZ Position: Q2 2019 in Review

Symmetry Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2019, closing a stake of 1,471 shares — an estimated $210K sold.

Symmetry Partners first reported a position in JAZZ in Q4 2018 and held it in 2 quarters. The position peaked at $210K in Q1 2019. 416 funds tracked by Wall St. Rank hold JAZZ as of Q2 2019.

  • Symmetry Partners reported no remaining Jazz Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Symmetry Partners sold 1,471 Jazz Pharmaceuticals shares in Q2 2019, an estimated $210K.
  • Symmetry Partners first reported a position in Jazz Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Symmetry Partners's Jazz Pharmaceuticals position peaked at $210K in Q1 2019.
  • 416 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2019.

Based on Symmetry Partners's 13F filing for Q2 2019, filed 7 Aug 2019.